You missed this? Then you’re not even up to speed rocky so why do you enable this basher?.
He said nothing accomplished at MDA last 2 years.
This has been posted before here Rocky—there’s more.
iopharm Oncology Presents Data on Very Rapid Production of CAR T Cells at Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond
Human CAR+ T cells with membrane-bound IL-15 manufactured in less than two days exhibited anti-tumor activity and persistence in pre-clinical studies
February 12, 2018 07:00 ET | Source: ZIOPHARM Oncology Inc
BOSTON, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP), a biotechnology company focused on development of next generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, today announced data demonstrating point-of-care (P-O-C) manufacturing of human T cells expressing chimeric antigen receptor (CAR) that persist and have an anti-tumor effect in preclinical models were presented at the Keystone Symposia Emerging Cellular Therapies: T Cells and Beyond in Keystone, Colorado.
The data presented showed T cells expressing CD19-specific CAR with membrane-bound IL-15 (mbIL15) were generated with the non-viral Sleeping Beauty system in less than two days and did not require ex vivo activation or propagation. T cells designed to express mbIL15 showed greater persistence and more potent antitumor activity than comparator T cells without mbIL15 in these studies.
Lenka V. Hurton, Ph.D., a researcher in the Division of Pediatrics at the University of Texas MD Anderson Cancer Center, presented the findings in a talk entitled, “Rapid production of T cells co-expressing CAR and membrane-bound IL-15 potentiates antitumor activity and promotes in vivo memory.” She also presented a poster under the same title during the Keystone Symposia.
Ziopharm is advancing its non-viral Sleeping Beauty platform towards using its point-of-care, or P-O-C, technology, a very rapid manufacturing process of genetically modified CAR+ T cells co-expressing mbIL15, with the first in-human trial utilizing this approach expected to commence in 2018. Ziopharm believes that manufacturing under P-O-C has the potential to reduce the costs associated with T-cell therapies and the potential to broaden application based on avoiding the need for centralized manufacturing as is the case when using a virus to genetically modify T cells.
Dr. Hurton’s poster and presentation slides are based on research conducted in collaboration with The University of Texas MD Anderson Cancer Center and Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (NYSE:XON). The poster is available in the Presentations and Publications section of the Company's website, www.ziopharm.co